Noah AI Secures Tens of Millions in Pre-A Funding to Advance AI Agents for Biopharmaceutical Innovation

VCBeat Exclusively Learns: Automated AI Pharmaceutical CompanyBeijing Ruosheng Intelligent Technology Co., Ltd. (hereinafter referred to as “Ruosheng Technology” or “Noah AI”), announced the completion of tens of millions of yuan in Pre-A round financing, led byOriza HoldingsLead Investor, Angel Round InvestorChaosheng CapitalContinued Investment.

Noah AI Official Website

Noah AI, founded in 2023, is dedicated to developing AI Agents for the healthcare industry, building intelligent agents capable of autonomous planning and user collaboration to support users in meeting a diverse range of needs—from medical inquiries to complex daily tasks in biomedicine. (Currently logged inhttps://www.noahai.co/Complete registration to enjoy a free trial).

Noah AI is composed of a team from leading global pharmaceutical companies, as well as AI and internet technology firms, integrating profound insights into the biopharmaceutical industry with extensive R&D experience in artificial intelligence. By integrating specialized workflows and professional data in the biopharmaceutical field, Noah AI has developed AI Agents capable of leveraging various industry-specific tools, empowering professionals to efficiently complete complex tasks.

Data in the biomedical field is extremely complex and diverse, spanning multiple disciplines including medicine, biology, and chemistry. AI Agents need to process and analyze this vast and heterogeneous data to provide valuable insights and predictions. However, current data processing and analysis techniques still face challenges, particularly in handling unstructured data and integrating data from disparate sources.

As a specialized AI agent in the biopharmaceutical vertical,Noah AI’s core competitiveness lies in its agent toolkit built upon industry-specific databases.Noah AI’s agent toolkit encompasses a suite of foundational tools and databases, including DCF valuation tools for pharmaceutical pipelines/companies, pipeline sales forecasting modeling tools, academic paper information, drug pipeline data, business development (BD) transaction data, and global clinical trial information. Each agent tool is built by the team based on professional workflows, methodologies, and years of industry expertise from human experts in the pharmaceutical sector. Integrated with Noah AI’s independently developed agent platform, these tools enable enterprise and individual users to rapidly execute professional tasks such as information retrieval, comparison, and even analysis.

Compared to other general artificial intelligence (AGI) or medical database products and software on the market, Noah AI serves more as a specialized consultant in the healthcare sector. It is capable of accepting complex, professional task instructions in the biomedical field. By learning from human experts’ analysis and decomposition of tasks, it refines these tasks and invokes relevant tools and resources for processing, thereby achieving true automated intelligent handling.

Currently, Noah AI has launched features such as WORKFLOW, DISCOVER, and EXPLORE to meet the fundamental needs of biopharmaceutical professionals, ranging from automation of complex tasks and processing of pharmaceutical information to medical information search.

Noah AI Clinical Data Analysis Features

Taking the WORKFLOW pipeline as an example, Noah AI has not only achieved automated extraction and preprocessing of key information from pharmaceutical data, but also enabled direct AI-driven automated analysis and comparison of clinical drug data, reducing information organization and analysis tasks that would otherwise take human personnel weeks to complete down to just a few minutes.

In addition to meeting users’ complex daily work needs in the biopharmaceutical industry, Noah AI has also developed the DISCOVER module, an AI-driven biopharmaceutical information platform.

This figure illustrates how the Noah AI Agent comprehensively reviewed over 5,000 study abstracts released at ASH 2024, organizing all key information—including trial titles, drug molecules, ORR, PFS, OS, AEs, other critical data, and conclusions—into easy-to-read cards equipped with AI-powered analytical interpretation capabilities.

The biopharmaceutical industry experiences rapid information iteration, with numerous important conferences held globally each month; in certain specialized fields, updates occur on a weekly basis. Accordingly, professionals in the biopharmaceutical sector must regularly monitor and analyze the latest disclosed R&D data to adjust or optimize their companies’ internal drug development plans and design strategies in a timely manner. Users can now track real-time highlights from major medical conferences (such as the ASH 2024 meeting shown in the figure above) directly on the Noah AI official website, and select corresponding data results within the AI query box for analysis and further questioning.

Interested parties are welcome to log in directly.https://www.noahai.co/Complete registration to enjoy free access to various Noah AI Agent features. You can also follow the WeChat official account “Ruosheng Technology” to stay updated on company and product news.

Regarding the securing of this round of financing,Wang Yinan, Founder and CEO of Noah AIStatement: Noah AI’s vision is to create AI employees and assistants capable of fully automating tasks in the pharmaceutical sector, enabling enterprises to efficiently perform knowledge work by employing these AI employees. By providing the industry with abundant, high-quality AI-driven productivity, Noah AI aims to accelerate the entire process from drug research and development to commercialization.

Zhao Qun, Partner at Oriza HoldingsIt is indicated that with the rapid iteration of foundational large language models (LLMs), there are greater opportunities for deploying AI applications in downstream vertical sectors. The biopharmaceutical sector is a highly promising vertical, characterized not only by high barriers to entry requiring specialized biomedical expertise but also by the daily handling of various complex tasks. With talent proficient in both large language models and the pharmaceutical industry, Noah AI is better positioned to empower transformation in the biopharmaceutical field. We look forward to Noah AI reshaping the future work paradigms for all professionals in the biopharmaceutical industry.

Zhou Yuexin, Managing Director of Chaosheng CapitalHangzhou Chaosheng Investment Management Co., Ltd. stated: “Chaosheng Capital has long focused on innovation opportunities in biotechnology and interdisciplinary fields. We are optimistic about the industry transformation driven by vertical applications of large language models. The Noah AI team possesses a highly interdisciplinary scientific background and extensive experience in both domestic and international pharmaceutical industries. We look forward to collaborating in the future to facilitate product commercialization and expand into global markets.”

Oriza Holdings, a market-oriented professional early-stage equity investment platform under Oriza Holdings Corporation, focuses on investment opportunities in start-ups and early-growth enterprises within the technology and healthcare sectors. With a total fund size exceeding RMB 7 billion, it manages both venture capital funds and region-specific angel funds. Since its establishment in 2013, Oriza Holdings has maintained an investment style characterized by a focus on early-stage ventures, a preference for technology-driven companies, and a steadfast commitment to its promises, earning a strong reputation among technology-focused early-stage start-ups. To date, it has invested in nearly 300 companies, dedicated to empowering entrepreneurial growth and developing alongside founders.

Nest.Bio Ventures is a venture capital and innovation incubation fund focused on the life sciences sector, dedicated to identifying revolutionary life science technologies and transforming them into globally impactful biotechnology companies through an innovation incubation model. Adhering to a hands-on investment philosophy, Nest.Bio serves as the closest partner to entrepreneurs, providing support to startup teams at various stages of growth. As an early-stage investor, Nest.Bio has identified, incubated, and invested in nearly forty cutting-edge biotechnology enterprises.

References:

1. "Bio Forward Series: Harnessing AI Agents for Your Benefit—Noah.AI Empowers In-Depth Research and Thinking in the Medical Field"

2. "nest.bio Member | Noah AI's New AGI Features Aid in Research Compilation and Interpretation for ASCO 2024"